Journal of Experimental Pharmacology (Nov 2020)
Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer
Abstract
Sarah K Cimino,1 Cathy Eng2 1Department of Pharmacy, Vanderbilt University Medical Center, Nashville, Tennessee, USA; 2Department of Medicine: Hematology/Oncology, Vanderbilt University Medical Center, Nashville, Tennessee, USACorrespondence: Sarah K CiminoDepartment of Pharmacy, Vanderbilt University Medical Center, 1301 Medical Center Drive, Nashville, TN 37232, USATel +1 615 875 6967Fax +1 615 343 8668Email [email protected]: Colorectal cancer is one of the top causes of cancer and cancer-related deaths worldwide. The prognosis of metastatic colorectal cancer is poor and treatment options are limited. Many patients will run out of treatment options before they become medically unfit for therapy. As such, there is a need to expand upon the current understanding of disease biology as well as drug resistance mechanisms in order to create new approaches for therapy. In this review article, we will discuss the mechanistic rationale and clinical data for new drugs and therapeutic combinations under development for metastatic colorectal cancer.Keywords: colon cancer, rectal cancer, drug resistance, novel combinations
